Perseverance through Advanced Melanoma: Clay Hummer
By Renee Orcione, MRA Digital Engagement & Communications Manager | 15 November 2023 In Melanoma Stories, Prevention, Science, Treatment
Clay Hummer is no stranger to perseverance, and his journey to today was not always easy. He gave up a career in law that he worked hard for to get completely sober and start a fresh chapter, moving to Texas in his 40s where he met the love of his life Christi. So, when he was diagnosed with melanoma shortly after his move, he knew quite a bit about overcoming a challenge.
Artificial Intelligence and Imaging in Melanoma Care: An Update
An early melanoma diagnosis is more likely to have a positive outcome than one diagnosed later. That’s a fact, but patients often delay having skin lesions checked for a variety of reasons, including long wait times to see a dermatologist—if they can even ﬁnd one close by.
A Message from Our CEO on Veterans Day
On this Veterans Day, we want to express our sincere gratitude and appreciation for the brave individuals who have served and sacrificed for our country. We also want to use today to raise awareness about the unique challenges faced by veterans when it comes to increased risk of developing melanoma,...
Melanoma Risk in the Military Community
By Renee Orcione, MRA Digital Engagement & Communications Manager | 9 November 2023 In News, Prevention, Science, Treatment
Ahead of Veterans Day, the Melanoma Research Alliance (MRA) wishes to recognize the brave individuals who have served and sacrificed for our country. As the largest private nonprofit funder of melanoma research worldwide, we are keenly aware of the important intersection between military service and melanoma.
Navy Veteran Ashlynn Soellner's Melanoma Journey
By Renee Orcione, MRA Digital Engagement & Communications Manager | 8 November 2023 In Melanoma Stories, Prevention, Treatment
Shortly after her active-duty career in the Navy came to an end, Ashlynn began noticing new moles on her body. She scheduled an appointment with her dermatologist, where a lesion on her shoulder was biopsied. Just a couple weeks later, she received an official diagnosis: she had melanoma. “You never think cancer will happen to you, especially when you are young. I was in complete shock,” said Ashlynn.
A History of Sunburns and an Early Stage Melanoma Diagnosis: Jill Roth
By Renee Orcione, MRA Digital Engagement & Communications Manager | 26 October 2023 In Melanoma Stories, Treatment
Jill Roth has lived her entire life in Dennison, Ohio. There, she grew up in a close-knit family, eventually started her own, and later became a caretaker to her elderly parents. Now retired, she looks back on her upbringing fondly – especially the countless summers spent by the pool.
What Melanoma Patients Need to Know about Hepzato Kit
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 23 October 2023 In News, Science, Treatment
You may have heard of Hepzato Kit, also known as Liver-Directed Melphalan, the first liver-directed therapy available for patients with metastatic uveal melanoma who have liver metastases that cannot be surgically removed.
Adjuvant Therapy: Is More Better or is Less More?
In 2021 and 2023, the FDA expanded approval of Keytruda and Opdivo, respectively, in the adjuvant setting to include more patients with melanoma — expanding therapeutic options for a greater number of patients. These decision have created tectonic shifts in the field—opening a range of not only treatment options but also discussion points to which the medical, research, and advocacy community are split.
Advancing Research after a Rare Diagnosis: Janet Yannelli's Acral Melanoma Journey
By Renee Orcione, MRA Digital Engagement & Communications Manager | 16 October 2023 In Allies & Partnerships, Melanoma Stories, Science, Treatment
“I had never heard of acral melanoma, even though I’m a nurse,” remarked Janet Yannelli, lifelong Maine resident. Acral melanoma is a rare melanoma subtype that accounts for about 1-3% of cases each year. Acral melanoma forms on the palms, soles of feet, or under nails.
MRA Statement on Expanded Approval of Nivolumab to Patients with Stage 2 Disease
The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the U.S. Food and Drug Administration (FDA) decision to expand eligibility of Bristol Myers Squibb’s Opdivo (nivolumab) to include patients with completely resected Stage IIB and IIC melanoma.